Response to COVID-19 mRNA Vaccination in Patients with Multiple Sclerosis on anti-CD20 Disease Modifying Therapies

被引：0
|
作者：
Wolf, Andrew [1 ]
Pratt, Robert W. [1 ]
Crooks, Kristy [2 ,3 ]
Borko, Tyler [1 ]
Gonzalez, Jose Parra [1 ]
Vollmer, Timothy [1 ]
Frazer-Abel, Ashley [4 ,5 ]
机构：
[1] Univ Colorado, Dept Neurol, Aurora, CO USA
[2] Univ Colorado, Sch Med, Colorado Mol Correlates Lab CMOCO, Aurora, CO USA
[3] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA
[4] Univ Colorado, Sch Med, Exsera BioLabs, Aurora, CO USA
[5] Univ Colorado, Sch Med, Dept Med, Div Rheumatol, Aurora, CO USA
来源：
ANNALS OF NEUROLOGY | 2021年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
340
引用
收藏
页码：S179 / S180
页数：2
相关论文
共 50 条
  • [21] Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
    Ali, Ahya
    Dwyer, Deanna
    Wu, Qi
    Wang, Qin
    Dowling, Catherine A.
    Fox, David A.
    Khanna, Dinesh
    Poland, Gregory A.
    Mao-Draayer, Yang
    VACCINE, 2021, 39 (41) : 6111 - 6116
  • [22] A personalized approach for anti-CD20 therapies in multiple sclerosis
    Hogenboom, Laura
    Kempen, Zoe L. E. van
    Kalincik, Tomas
    Bar-Or, Amit
    Killestein, Joep
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [23] COVID-19 pandemic: multiple sclerosis patients under disease-modifying therapies
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 58 - 58
  • [24] COVID-19 vaccines and multiple sclerosis disease-modifying therapies
    Giovannoni, Gavin
    Hawkes, Christopher H.
    Lechner-Scott, Jeannette
    Levy, Michael
    Yeh, E. Ann
    Baker, David
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 53
  • [25] Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era
    Ciotti, John R.
    Grebenciucova, Elena
    Moss, Brandon P.
    Newsome, Scott D.
    ANNALS OF NEUROLOGY, 2020, 88 (06) : 1062 - 1064
  • [26] COVID-19 and multiple sclerosis - prevalence and the impact of disease modifying therapies
    Kieseier, B.
    Rajbhandari, R.
    Altincatal, A.
    Kim, M.
    Berdofe, A.
    Radhakrishnan, M.
    Jung, E.
    Sandrock, A.
    De Moor, C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 102 - 103
  • [27] Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Achiron, Anat
    Mandel, Mathilda
    Dreyer-Alster, Sapir
    Harari, Gil
    Magalashvili, David
    Sonis, Polina
    Dolev, Mark
    Menascu, Shay
    Flechter, Shlomo
    Falb, Rina
    Gurevich, Michael
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [28] Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
    Dominelli, Federica
    Zingaropoli, Maria Antonella
    Tartaglia, Matteo
    Tortellini, Eeva
    Guardiani, Mariasilvia
    Perri, Valentina
    Pasculli, Patrizia
    Ciccone, Federica
    Malimpensa, Leonardo
    Baione, Viola
    Napoli, Anna
    Gaeta, Aurelia
    Lichtner, Miriam
    Conte, Antonella
    Mastroianni, Claudio Maria
    Ciardi, Maria Rosa
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [29] Disease Modifying Therapy Choice in People with Multiple Sclerosis in The Era of Covid: Characterizing Outcomes in Patients who Switched from anti-CD20 Therapies to Diroximel Fumarate
    Kaczmarek, O.
    Sethi, A.
    Teng, E.
    Bumstead, B.
    Buhse, M.
    Zarif, M.
    Scott, N.
    Gocke, A.
    Mendoza, J. P.
    Gudesblatt, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 78 - 79
  • [30] Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
    de Seze, Jerome
    Maillart, Elisabeth
    Gueguen, Antoine
    Laplaud, David A. A.
    Michel, Laure
    Thouvenot, Eric
    Zephir, Helene
    Zimmer, Luc
    Biotti, Damien
    Liblau, Roland
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345